Efficacy and safety of Buzhong Yiqi decoction combined with western medicine in the treatment of myasthenia gravis
Open Access
- 19 March 2021
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 100 (11), e24807
- https://doi.org/10.1097/md.0000000000024807
Abstract
Background: Myasthenia gravis is a common autoimmune disease in clinic. Although there are various ways and drugs for the treatment of myasthenia gravis in Western medicine, there are still a variety of adverse reactions. Studies have shown that Buzhong Yiqi decoction combined with Western medicine has a certain efficacy in the treatment of myasthenia gravis, but there is a lack of evidence-based medicine. The research carried out in this scheme is to systematically evaluate the efficacy and safety of Buzhong Yiqi decoction combined with Western medicine in the treatment of myasthenia gravis, and to provide reliable evidence for guiding clinical practice. Methods: English databases (the Cochrane Library, PubMed, Web of Science, Embase) and Chinese databases (China Biomedical Database, China Science and Technology Journal Database, China National Knowledge Infrastructure, Wanfang) will be searched by computer. In addition, Baidu Academic and Chinese Clinical Trial Registration Center will be searched manually. A randomized controlled clinical trial of Buzhong Yiqi decoction combined with Western medicine in the treatment of myasthenia gravis will be conducted from the establishment of the database to December 2020. The 2 researchers independently carry out data extraction and literature quality evaluation on the quality of the included study, and meta-analysis of the included literature will be carried out by using RevMan 5.3 software. Results: This study will evaluate the efficacy and safety of Buzhong Yiqi decoction combined with Western medicine in the treatment of myasthenia gravis by Quantitive MGscore, the number of Tregs cells and the content of anti-acetylcholine receptor antibody (AchR-Ab). Conclusion: This study will provide reliable evidence-based evidence for the clinical application of Buzhong Yiqi decoction combined with Western medicine in the treatment of myasthenia gravis. Ethics and dissemination: Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval was not required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences. OSF Registration number: DOI 10.17605/OSF.IO/MXUPK.Funding Information
- Yantai city key research and development projects (2018XDHZ101)
This publication has 19 references indexed in Scilit:
- Decreased expression of miR-29 family associated with autoimmune myasthenia gravisJournal of Neuroinflammation, 2020
- Myasthenia Gravis and Large Granular Lymphocytic Leukemia: a rare associationLeukemia Research Reports, 2020
- Differential Gut Microbiota and Fecal Metabolites Related With the Clinical Subtypes of Myasthenia GravisFrontiers in Microbiology, 2020
- Desafios perioperatórios e pontos de atenção no bloqueio neuromuscular durante timectomia robótica para miastenia gravisRevista Brasileira de Anestesiologia, 2020
- Myasthenia Gravis and its Association With Thyroid DiseasesCureus, 2020
- Case Series: A case of familial thymomatous myasthenia gravis in a family of three male brothersJournal of Surgical Case Reports, 2020
- Fatigue, self-efficacy and psychiatric symptoms influence the quality of life in patients with myasthenia gravis in Tianjin, ChinaJournal of Clinical Neuroscience, 2020
- Role of Thymus on Prognosis of Myasthenia Gravis in Turkish PopulationNorthern Clinics of Istanbul, 2020
- Ecchymosis: A novel sign in patients with varicose veinsClinical Hemorheology and Microcirculation, 2018